|
|
 |
| |
2008 Annual Meeting Abstracts
Chromosome 17q12 Genetic Variants, Diabetes, and Prostate Cancer Aggressiveness
Stacy Loeb1, Brian T. Helfand2, Donghui Kan*2, William J. Catalona2
1Johns Hopkins Medical Institutions, Baltimore, MD;2Northwestern University, Chicago, IL
Introduction: Epidemiological studies have suggested an inverse relationship between diabetes and prostate cancer (CaP) risk. A newly discovered CaP susceptibility locus on chromosome 17q12 (SNP rs4430796) is located within the TCF2 gene. This locus also confers protection against type 2 diabetes, potentially explaining some of the observed link between these conditions. Less is known about the effect of diabetes mellitus (DM) on CaP features among carriers and non-carriers of these 17q12 risk alleles.
Methods: From a radical prostatectomy series, we identified 593 genotyped men with information on DM. We evaluated the relationship between rs4430796 carrier status, DM, and treatment outcomes.
Results: Approximately 7% of the study population had DM. Although BMI was higher in diabetic patients, pathological tumor features were similar regardless of DM status. 17q12 carriers were significantly more likely to have a prostatectomy Gleason score ≥7. DM did not affect the likelihood of adverse outcomes among carriers or noncarriers of the 17q12 susceptibility alleles.
Conclusions: DM was not related to treatment outcomes in this cohort. However, there were relatively few men with diabetes in our prostatectomy database, particularly compared with the prevalence of diabetes in up to 21% of the U.S. population over age 60. This may reflect selection bias, genetic protection from CaP among diabetic patients, or both. Despite these limitations, our data suggest that diabetes status alone does not appear to correlate with disease-specific outcomes among carriers and non-carriers of the 17q12 susceptibility genes with clinically localized CaP.
|
|
| |
|
|
| |
|
|
|
|
